Results 111 to 120 of about 49,427 (236)

The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes [PDF]

, 2018
Caroline McNamara, Tony Panzarella, Theodore A. Kennedy, Andrea Arruda, Jaime O. Claudio, Georgina S. Daher-Reyes, Jenny Ho, Nancy Siddiq, Rebecca Devlin, Hubert Tsui, Jie Su, Tracy Stockley, Mahadeo A. Sukhai, Nisha Kanwar, Steven M. Chan, Dawn Maze, Aaron D. Schimmer, Andre C. Schuh, Hassan Sibai, Auro Viswabandya, Karen Yee, Mark D. Minden, Suzanne Kamel‐Reid, Vikas Gupta   +23 more
openalex   +1 more source

Clinical Implications of Plasma-Derived Extracellular Vesicles in Myeloproliferative Neoplasms: Unveiling Inflammatory Potential and Biomarkers for Cancer Treatment [PDF]

Ghazal Narimanfar, Dorian Forte, Roberto Maria Pellegrino, Francesca Perut, Filippo Maltoni, Martina Barone, Alessia Brancolini, Filippo Branzanti, Vincenzo Pucci, Elisabetta Lugli, Alessia Tieghi, Carla Emiliani, Johannes Grillari, Pier Luigi Zinzani, Francesca Palandri, Lucia Catani   +15 more
openalex   +1 more source

Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms [PDF]

, 2021
Laura Palomo, Pamela Acha, Françesc Solé   +2 more
openalex   +1 more source

An agenda for future research projects in polycythemia vera and essential thrombocythemia

Haematologica, 2020
Tiziano Barbui, Alessandro Maria Vannucchi, Paola Guglielmelli, Valerio De Stefano, Alessandro Rambaldi   +4 more
doaj   +1 more source

Evaluation of the association between the JAK2 46/1 haplotype and chronic myeloproliferative neoplasms in a Brazilian population

Clinics, 2013
OBJECTIVE: The JAK2 46/1 haplotype has recently been described as a major contributing factor to the development of myeloproliferative neoplasm, whether positive or negative forthe JAK2 V617F mutation.
Sarah Pagliarini-e-Silva, Bruna Cunha Santos, Elizangela Mendes de Figueiredo Pereira, Mari Ellen Ferreira, Elaine Cristina Baraldi, Ana Maria Sell, Jeane Eliete Laguila Visentainer   +6 more
doaj  

The G allele of the JAK2 rs10974944 SNP, part of JAK2 46/1 haplotype, is strongly associated with JAK2 V617F-positive myeloproliferative neoplasms

, 2010
Adrian P. Trifa, Andrei Cucuianu, L. N. Petrov, Laura Urian, Mariela Militaru, Delia Dima, Ioan Pop, Radu A. Popp   +7 more
openalex   +2 more sources

A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms [PDF]

, 2017
Rita Assi, Hagop M. Kantarjian, Guillermo Garcia‐Manero, Jörge E. Cortes, Naveen Pemmaraju, Xuemei Wang, Graciela M. Nogueras‐González, Elias Jabbour, Prithviraj Bose, Tapan M. Kadia, Courtney D. DiNardo, Keyur P. Patel, Carlos E. Bueso‐Ramos, Lingsha Zhou, Sherry Pierce, Romany Gergis, Carla Tuttle, Gautam Borthakur, Zeev Estrov, Rajyalakshmi Luthra, Juliana E. Hidalgo‐Lόpez, Srđan Verstovšek, Naval Daver   +22 more
openalex   +1 more source

Patient-reported outcomes data from REVEAL at the time of enrollment (baseline): A prospective observational study of patients with polycythemia vera in the United States [PDF]

, 2018
Boccia, Ralph V, Colucci, Philomena, Grunwald, Michael R, Mesa, Ruben, Oh, Stephen T, Paranagama, Dilan, Parasuraman, Shreekant, Stein, Brady L   +7 more
core   +2 more sources

Evaluation of bone marrow morphology is essential for assessing disease status in recombinant interferon α-treated polycythemia vera patients

Haematologica, 2017
Elizabeth Margolskee, Spencer Krichevsky, Attilio Orazi, Richard T. Silver   +3 more
doaj   +1 more source

Molecular genetic evaluation of myeloproliferative neoplasms [PDF]

, 2015
Elizabeth M. Azzato, Adam Bagg
openalex   +1 more source